Para-aminobenzoic acid - PABA - 'Sunscreen Vitamin' Information

PABA is an antioxidant vitamin related to folic acid. It is the 'sunscreen' vitamin used in sunscreen preparations, as it has the ability to protect the skin against excessive ultra-violet light exposure. No recommended daily allowances for PABA have been established, but an allowance of between 30 mg and 100 mg is considered reasonable.

PABA Benefits

It is known for its ability to absorb ultraviolet (UV) light, thus preventing wrinkling of the skin and reducing the risk of skin cancer. It is therefore widely used in sun block preparations. It corrects loss of pigmentation in skin and hair, prevents hair greying and retards hair loss. It also protects the lungs from ozone damage, acts as a coenzyme in the utilization of protein, assists in the formation of red blood cells and enhances the formation of folic acid in the intestine.

PABA Deficiency Symptoms

They include skin conditions such as eczema and wrinkles, fatigue, irritability and depression, senility, arthritis and bursitis.

PABA Food Sources

Its best natural sources are molasses, brewer's yeast, liver, whole grains and eggs. It can also be made by intestinal bacteria. Any excess is stored in the body.

PABA Supplements

In spite of the fact that the body synthesizes PABA, it may not be sufficient for maximum protection and therefore PABA supplements can usefully enhance its beneficial effects. It is best taken as part of a balanced B-vitamin tablet or capsule, unless your doctor or nutritional health practitioner advises otherwise.

Leave your comments

Health News

Surgeon Removes Eight Pound Liver Tumor

The cancerous tumor in Marcus Muhich's liver weighed 8 pounds and was nearly a foot across. Doctors at three major academic medical centers in the Midwest told Muhich his high-grade tumor was inoperable. Then he was referred to Dr... [ read article ]

NIPPV Linked To Increased Hospital Mortality Rates In Small Group Of Patients

Although increased use of noninvasive positive-pressure ventilation (NIPPV) nationwide has helped decrease mortality rates among patients hospitalized with chronic obstructive pulmonary disease (COPD), a small group of... [ read article ]

FDA Approves Label Update For PREZISTA® To Include 192-Week Data In HIV-1-Infected Adult Patients

Starting Treatment Janssen Therapeutics, Division of Janssen Products, LP, announced that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA® (darunavir) tablets to include 192-week data from the ARTEMIS study... [ read article ]

Recommended Stuff

Our Latest Blog Entries...